Skip to main content
Shenzhen Bioeasy Biotechnology Co., Ltd. logo

Shenzhen Bioeasy Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 300942 ISIN · CNE100004C78 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 910 across all filing types
Latest filing 2025-08-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300942

About Shenzhen Bioeasy Biotechnology Co., Ltd.

https://www.bioeasy.com

Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development, production, and marketing of rapid testing solutions for food safety, clinical diagnosis, and animal health. The company provides a comprehensive portfolio of diagnostic products, including rapid test strips, enzyme-linked immunosorbent assay (ELISA) kits, and automated detection instruments. Its core focus areas include the detection of antibiotic residues, mycotoxins, pesticides, and foodborne pathogens in dairy, meat, seafood, and grain products. In the clinical sector, Bioeasy offers point-of-care testing (POCT) solutions for infectious diseases and chronic conditions. The company emphasizes research and development to deliver high-sensitivity, user-friendly diagnostic tools that meet international quality standards. Its products are utilized by food producers, regulatory agencies, and healthcare providers to ensure safety and quality control across the global supply chain.

Recent filings

Filing Released Lang Actions
关于“易瑞转债”预计触发赎回条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shenzhen Yirui Biological Technology Co., Ltd. regarding the potential triggering of conditional redemption clauses for its convertible bonds (referred to as '易瑞转债'). It details the bond issuance, listing, conversion price adjustments, and the conditions under which the company may redeem the bonds early. The document is an informative notice about a possible future financial action (redemption of convertible bonds) and includes risk warnings for investors. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but an announcement related to capital/financing activities, specifically about convertible bond redemption conditions and potential redemption triggers. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 2446 characters, which is consistent with an announcement rather than a full report.
2025-08-13 Chinese
关于注销及开立募集资金现金管理专用结算账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding the cancellation and opening of special settlement accounts for cash management of raised funds. It details decisions made by the board and shareholders about the use of idle raised funds and own funds for cash management, including specific account information and regulatory compliance references. The document is a formal announcement about changes in the management of raised funds accounts, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It fits the category of Capital/Financing Update (CAP) as it relates to the company's fundraising and capital management activities.
2025-08-13 Chinese
关于“易瑞转债”2025年付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on a convertible bond issued by Shenzhen EasyBio Technology Co., Ltd. It details the interest payment date, interest rate, bond issuance details, tax information, and payment procedures. The document is relatively short (3840 characters) and focuses on a specific financing event related to bond interest payment. It does not contain comprehensive financial statements or management discussion, nor is it a full financial report. It is not a report publication announcement but a specific update on financing activity related to convertible bonds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-11 Chinese
关于注销及开立募集资金现金管理专用结算账户的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Yirui Biotechnology Co., Ltd. regarding the cancellation and opening of special settlement accounts for cash management of raised funds. It details decisions made by the board and shareholders about the use of idle raised funds for cash management, the closure of a previous account, and the opening of a new account. The document references regulatory rules about fund management and provides specific bank account information. It does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about capital management activities related to raised funds, specifically about cash management accounts. This fits best under Capital/Financing Update (CAP) as it concerns the management and use of capital raised by the company, not a full financial report or other categories like Annual Report or Earnings Release.
2025-08-04 Chinese
关于控股股东、实际控制人及其一致行动人权益变动触及1%整数倍的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from Shenzhen Yirui Biotechnology Co., Ltd. regarding changes in shareholding by the controlling shareholder, actual controller, and their concerted parties. It details the reduction in shares held, the percentage changes, and compliance with relevant securities laws and regulations. The document includes specific shareholding numbers, dates of transactions, and confirms that the changes do not affect control or governance structure. It is a notification about changes in major shareholding levels, specifically mentioning crossing a 1% threshold. The document length is 3655 characters, which is relatively short and focused solely on shareholding changes without financial statements or management discussion. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2025-08-01 Chinese
关于开立募集资金现金管理专用结算账户的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Yirui Biotechnology Co., Ltd. regarding the opening of a dedicated settlement account for cash management of raised funds. It details board approvals related to the use of idle raised funds and own funds for cash management, the account information, and compliance with regulatory rules. The document is short (1025 characters) and primarily serves as an announcement of a corporate action related to capital management, not a full financial report or detailed financial data. It does not contain financial statements or detailed analysis, nor is it a report publication or certification. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-07-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.